Akebia Therapeutics Stock Forecast, Price & News

Akebia Therapeutics' stock was trading at $6.94 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AKBA shares have decreased by 68.0% and is now trading at $2.22.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akebia Therapeutics in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Akebia Therapeutics.

Akebia Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Akebia Therapeutics.

Akebia Therapeutics will be holding an earnings conference call on Thursday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) announced its quarterly earnings data on Monday, August, 10th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.46) by $0.02. The biopharmaceutical company earned $90.14 million during the quarter, compared to analyst estimates of $76.24 million. Akebia Therapeutics had a negative net margin of 113.35% and a negative return on equity of 55.64%.
View Akebia Therapeutics' earnings history.

7 analysts have issued 12-month target prices for Akebia Therapeutics' stock. Their forecasts range from $3.00 to $18.00. On average, they anticipate Akebia Therapeutics' share price to reach $10.29 in the next year. This suggests a possible upside of 363.3% from the stock's current price.
View analysts' price targets for Akebia Therapeutics.

Akebia Therapeutics saw a increase in short interest during the month of September. As of September 30th, there was short interest totaling 22,170,000 shares, an increase of 141.8% from the September 15th total of 9,170,000 shares. Based on an average daily volume of 5,120,000 shares, the short-interest ratio is currently 4.3 days.
View Akebia Therapeutics' Short Interest.

Some companies that are related to Akebia Therapeutics include Epizyme (EPZM), Amneal Pharmaceuticals (AMRX), Myovant Sciences (MYOV), Mersana Therapeutics (MRSN), Trillium Therapeutics (TRIL), Theravance Biopharma (TBPH), Generation Bio (GBIO), NGM Biopharmaceuticals (NGM), Zogenix (ZGNX), Phathom Pharmaceuticals (PHAT), Keros Therapeutics (KROS), Innoviva (INVA), Karyopharm Therapeutics (KPTI), Cytokinetics (CYTK) and Kiniksa Pharmaceuticals (KNSA).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Akebia Therapeutics investors own include Novavax (NVAX), Gilead Sciences (GILD), AbbVie (ABBV), Energy Transfer (ET), Micron Technology (MU), TherapeuticsMD (TXMD), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), NVIDIA (NVDA) and AT&T (T).

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State of New Jersey Common Pension Fund D (0.15%), DekaBank Deutsche Girozentrale (0.07%), Dupont Capital Management Corp (0.07%), Candriam Luxembourg S.C.A. (0.05%), Alpha Windward LLC (0.03%) and BNP Paribas Arbitrage SA (0.02%). Company insiders that own Akebia Therapeutics stock include Dell Faulkingham, Jason Amello, John P Butler, Maxine Gowen, Michel Dahan, Nicole R Hadas, Steven C Gilman and Steven Keith Burke.
View institutional ownership trends for Akebia Therapeutics.

AKBA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A.. Company insiders that have sold Akebia Therapeutics company stock in the last year include Dell Faulkingham, Jason Amello, Maxine Gowen, Michel Dahan, and Nicole R Hadas.
View insider buying and selling activity for Akebia Therapeutics.

AKBA stock was purchased by a variety of institutional investors in the last quarter, including DekaBank Deutsche Girozentrale, Dupont Capital Management Corp, State of New Jersey Common Pension Fund D, BNP Paribas Arbitrage SA, Alpha Windward LLC, XTX Markets LLC, and Wedbush Securities Inc.. Company insiders that have bought Akebia Therapeutics stock in the last two years include John P Butler, Steven C Gilman, and Steven Keith Burke.
View insider buying and selling activity for Akebia Therapeutics.

Shares of AKBA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AKBA stock can currently be purchased for approximately $2.22.

Akebia Therapeutics has a market capitalization of $318.17 million and generates $335 million in revenue each year. The biopharmaceutical company earns $-279,660,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Akebia Therapeutics employs 358 workers across the globe.

The official website for Akebia Therapeutics is www.akebia.com.

Akebia Therapeutics' mailing address is 245 FIRST STREET SUITE 1100, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 617-871-2098 or via email at [email protected]